The U.S. Food and Drug Administration on Friday approved German drugmaker Boehringer Ingelheim's Ofev capsules for a rare lung disorder. The drug is first FDA-approved treatment for this condition, the FDA said in a statement. The drug is aimed at slowing the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis, an autoimmune condition. Ofev was originally approved in 2014 for adult patients with idiopathic pulmonary fibrosis, which is another interstitial lung condition.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!